

# Susan L Cohn

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/358758/publications.pdf>

Version: 2024-02-01

192  
papers

17,538  
citations

22548

61  
h-index

17373

126  
g-index

194  
all docs

194  
docs citations

194  
times ranked

12943  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Experience of Children With Neuroblastoma and Their Parents During Single-Room Isolation for <sup>131</sup> I-Metaiodobenzylguanidine Therapy: A Qualitative Descriptive Study. , 2022, 39, 304-316.		3
2	Rethinking high-risk neuroblastoma treatment. Pediatric Blood and Cancer, 2022, 69, e29730.	0.8	1
3	Efficacy of post-induction therapy for high-risk neuroblastoma patients with end-induction residual disease. Cancer, 2022, 128, 2967-2977.	2.0	5
4	Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2022, 40, 4107-4118.	0.8	11
5	A nomogram of clinical and biologic factors to predict survival in children newly diagnosed with high-risk neuroblastoma: An International Neuroblastoma Risk Group project. Pediatric Blood and Cancer, 2021, 68, e28794.	0.8	29
6	Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032. Clinical Cancer Research, 2021, 27, 2179-2189.	3.2	95
7	Revised Neuroblastoma Risk Classification System: A Report From the Children's Oncology Group. Journal of Clinical Oncology, 2021, 39, 3229-3241.	0.8	174
8	Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma. , 2021, 9, e002417.		21
9	Association Between Participation in Clinical Trials and Overall Survival Among Children With Intermediate- or High-risk Neuroblastoma. JAMA Network Open, 2021, 4, e2116248.	2.8	5
10	Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium. Journal of Clinical Oncology, 2021, 39, 3506-3514.	0.8	38
11	Pediatric Cancer Data Commons: Federating and Democratizing Data for Childhood Cancer Research. JCO Clinical Cancer Informatics, 2021, 5, 1034-1043.	1.0	18
12	Stage 4S Neuroblastoma. American Journal of Surgical Pathology, 2021, 45, 1075-1081.	2.1	10
13	Predicting Response to Chemotherapy in Patients With Newly Diagnosed High-Risk Neuroblastoma: A Report From the International Neuroblastoma Risk Group. JCO Clinical Cancer Informatics, 2021, 5, 1181-1188.	1.0	3
14	5-Hydroxymethylcytosine Profiles in Circulating Cell-Free DNA Associate with Disease Burden in Children with Neuroblastoma. Clinical Cancer Research, 2020, 26, 1309-1317.	3.2	22
15	Unrealistic parental expectations for cure in poor-prognosis childhood cancer. Cancer, 2020, 126, 416-424.	2.0	34
16	Tailoring Therapy for Children With Neuroblastoma on the Basis of Risk Group Classification: Past, Present, and Future. JCO Clinical Cancer Informatics, 2020, 4, 895-905.	1.0	36
17	Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients. Pediatric Blood and Cancer, 2020, 67, e28390.	0.8	6
18	Reply to K. Beiske et al. Journal of Clinical Oncology, 2020, 38, 3720-3721.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Paraneoplastic opsoclonus myoclonus syndrome associated with inflammatory myofibroblastic tumor in a pediatric patient. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28218.	0.8	1
20	The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28359.	0.8	28
21	Racial and Ethnic Differences in Communication and Care for Children With Advanced Cancer. <i>Journal of Pain and Symptom Management</i> , 2020, 60, 782-789.	0.6	27
22	Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project. <i>Journal of Clinical Oncology</i> , 2020, 38, 1906-1918.	0.8	41
23	Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children's Oncology Group Study ANBL0531. <i>Journal of Clinical Oncology</i> , 2019, 37, 3243-3255.	0.8	61
24	Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma. <i>Molecular Cancer Therapeutics</i> , 2019, 18, 507-516.	1.9	22
25	5-Hydroxymethylcytosine Profiles Are Prognostic of Outcome in Neuroblastoma and Reveal Transcriptional Networks That Correlate With Tumor Phenotype. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	14
26	Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531. <i>Journal of Clinical Oncology</i> , 2019, 37, 115-124.	0.8	45
27	Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27736.	0.8	8
28	The challenge of defining "ultra-high-risk" neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27556.	0.8	43
29	Neuroblastoma Patients' KIR and KIR-Ligand Genotypes Influence Clinical Outcome for Dinutuximab-based Immunotherapy: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2018, 24, 189-196.	3.2	45
30	Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 25-34.	2.7	38
31	Immune Reconstitution Following Autologous Stem Cell Transplantation in Patients with High-Risk Neuroblastoma at the Time of Immunotherapy. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 452-459.	2.0	10
32	Statistical Framework in Support of a Revised Children's Oncology Group Neuroblastoma Risk Classification System. <i>JCO Clinical Cancer Informatics</i> , 2018, 2, 1-15.	1.0	20
33	Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2018, 65, e27417.	0.8	4
34	Phase II Trial of Alisertib in Combination with Irinotecan and Temozolomide for Patients with Relapsed or Refractory Neuroblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 6142-6149.	3.2	55
35	MYC-family protein overexpression and prominent nucleolar formation represent prognostic indicators and potential therapeutic targets for aggressive high-MK1 neuroblastomas: a report from the children's oncology group. <i>Oncotarget</i> , 2018, 9, 6416-6432.	0.8	31
36	The Role of Nursing Professionals in the Management of Patients With High-Risk Neuroblastoma Receiving Dinutuximab Therapy. <i>Journal of Pediatric Oncology Nursing</i> , 2017, 34, 160-172.	1.5	2

#	ARTICLE	IF	CITATIONS
37	Emerging and investigational therapies for neuroblastoma. Expert Opinion on Orphan Drugs, 2017, 5, 355-368.	0.5	27
38	Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project. European Journal of Cancer, 2017, 72, 177-185.	1.3	59
39	Composite tumor with pheochromocytoma and immature neuroblastoma: report of two cases with cytogenetic analysis and discussion of current terminology. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 471, 553-557.	1.4	9
40	Evaluation of Genetic Predisposition for MYCN-Amplified Neuroblastoma. Journal of the National Cancer Institute, 2017, 109, .	3.0	20
41	Rebound thymic hyperplasia following high dose chemotherapy and stem cell transplant in three neuroblastoma patients. Pediatric Blood and Cancer, 2017, 64, e26226.	0.8	5
42	Data Commons to Support Pediatric Cancer Research. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 746-752.	1.8	25
43	Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. Journal of Clinical Oncology, 2017, 35, 2580-2587.	0.8	219
44	Data Commons to Support Pediatric Cancer Research. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 746-752.	1.8	20
45	Genetic discoveries and treatment advances in neuroblastoma. Current Opinion in Pediatrics, 2016, 28, 19-25.	1.0	44
46	Segmental Chromosomal Aberrations in Localized Neuroblastoma Can be Detected in Formalin-Fixed Paraffin-Embedded Tissue Samples and Are Associated With Recurrence. Pediatric Blood and Cancer, 2016, 63, 1019-1023.	0.8	13
47	A Phase I New Approaches to Neuroblastoma Therapy Study of Buthionine Sulfoximine and Melphalan With Autologous Stem Cells for Recurrent/Refractory High-Risk Neuroblastoma. Pediatric Blood and Cancer, 2016, 63, 1349-1356.	0.8	66
48	Prognostic significance of pattern and burden of metastatic disease in patients with stage 4 neuroblastoma: A study from the International Neuroblastoma Risk Group database. European Journal of Cancer, 2016, 65, 1-10.	1.3	56
49	Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy. Cancer Chemotherapy and Pharmacology, 2016, 77, 405-412.	1.1	24
50	Integrative genomics reveals hypoxia inducible genes that are associated with a poor prognosis in neuroblastoma patients. Oncotarget, 2016, 7, 76816-76826.	0.8	33
51	Secreted protein acidic and rich in cysteine (SPARC) induces lipotoxicity in neuroblastoma by regulating transport of albumin complexed with fatty acids. Oncotarget, 2016, 7, 77696-77706.	0.8	14
52	Identification of different ALK mutations in a pair of neuroblastoma cell lines established at diagnosis and relapse. Oncotarget, 2016, 7, 87301-87311.	0.8	20
53	A Selfless Act. Journal of Clinical Oncology, 2015, 33, 3834-3835.	0.8	2
54	In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clinic Proceedings, 2015, 90, 996-1000.	1.4	128

#	ARTICLE	IF	CITATIONS
55	Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma. <i>Clinical Cancer Research</i> , 2015, 21, 2715-2721.	3.2	62
56	Stem Cell Transplant-Associated Wernicke Encephalopathy in a Patient with High-Risk Neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 2232-2234.	0.8	6
57	Surveillance of Childhood Cancer Survivors: A Lifelong Affair. <i>Journal of Clinical Oncology</i> , 2015, 33, 3531-3532.	0.8	5
58	Advances in Risk Classification and Treatment Strategies for Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2015, 33, 3008-3017.	0.8	637
59	Second malignancies in patients with neuroblastoma: The effects of risk-based therapy. <i>Pediatric Blood and Cancer</i> , 2015, 62, 128-133.	0.8	51
60	Efavirenz but not nevirapine-based antiretroviral therapy decreases exposure to the levonorgestrel released from a subdermal contraceptive implant. <i>Journal of the International AIDS Society</i> , 2014, 17, 19484.	1.2	23
61	Age-Dependent Prognostic Effect by Mitosis-Karyorrhexis Index in Neuroblastoma: A Report from the Children's Oncology Group. <i>Pediatric and Developmental Pathology</i> , 2014, 17, 441-449.	0.5	35
62	Treatment of two cases with refractory, metastatic intermediate-risk neuroblastoma with isotretinoin alone or observation. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1104-1106.	0.8	5
63	Time to disease progression in children with relapsed or refractory neuroblastoma treated with <sup>131</sup> I-ABT-51: A report from the Children's Oncology Group (ANBL0621). <i>Pediatric Blood and Cancer</i> , 2014, 61, 990-996.	0.8	16
64	Secondary malignant neoplasms after high-dose chemotherapy and autologous stem cell rescue for high-risk neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1350-1356.	0.8	40
65	Neuroblastoma in older children, adolescents and young adults: A report from the International Neuroblastoma Risk Group project. <i>Pediatric Blood and Cancer</i> , 2014, 61, 627-635.	0.8	71
66	Metastatic Neuroblastoma Confined to Distant Lymph Nodes (stage 4N) Predicts Outcome in Patients With Stage 4 Disease: A Study From the International Neuroblastoma Risk Group Database. <i>Journal of Clinical Oncology</i> , 2014, 32, 1228-1235.	0.8	28
67	Clinical, Biologic, and Prognostic Differences on the Basis of Primary Tumor Site in Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. <i>Journal of Clinical Oncology</i> , 2014, 32, 3169-3176.	0.8	154
68	Significance of clinical and biologic features in Stage 3 neuroblastoma: A report from the International Neuroblastoma Risk Group project. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1932-1939.	0.8	32
69	Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter <sup>®</sup> system. <i>Molecular Oncology</i> , 2014, 8, 669-678.	2.1	32
70	TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma. <i>Cell Reports</i> , 2014, 7, 1343-1352.	2.9	146
71	Secreted Protein Acidic and Rich in Cysteine. , 2014, , 1-6.		0
72	Secreted Protein Acidic and Rich in Cysteine. , 2014, , 4147-4151.		0

#	ARTICLE	IF	CITATIONS
73	Peripheral neuroblastic tumors with genotype-phenotype discordance: A report from the Children's Oncology Group and the International Neuroblastoma Pathology Committee. <i>Pediatric Blood and Cancer</i> , 2013, 60, 363-370.	0.8	25
74	Children's Oncology Group's 2013 blueprint for research: Neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2013, 60, 985-993.	0.8	285
75	Progression-free survival of two cases of high-risk neuroblastoma with refractory/relapsed disease following surgery alone. <i>Pediatric Blood and Cancer</i> , 2013, 60, 512-514.	0.8	0
76	Purged versus non-purged peripheral blood stem-cell transplantation for high-risk neuroblastoma (COG A3973): a randomised phase 3 trial. <i>Lancet Oncology</i> , 2013, 14, 999-1008.	5.1	246
77	Semiquantitative mlBG Scoring as a Prognostic Indicator in Patients with Stage 4 Neuroblastoma: A Report from the Children's Oncology Group. <i>Journal of Nuclear Medicine</i> , 2013, 54, 541-548.	2.8	169
78	Two cases of localized neuroblastoma with multiple segmental chromosomal alterations and metastatic progression. <i>Pediatric Blood and Cancer</i> , 2013, 60, 332-335.	0.8	3
79	Neuroblastoma of undifferentiated subtype, prognostic significance of prominent nucleolar formation, and MYC/MYCN protein expression: A report from the Children's Oncology Group. <i>Cancer</i> , 2013, 119, 3718-3726.	2.0	67
80	Genetically Informed Therapies: A "GIFT" for Children with Cancer. <i>Clinical Cancer Research</i> , 2012, 18, 2735-2739.	3.2	7
81	Trans-population Analysis of Genetic Mechanisms of Ethnic Disparities in Neuroblastoma Survival. <i>Journal of the National Cancer Institute</i> , 2012, 105, 302-309.	3.0	30
82	A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants. <i>Annals of Surgery</i> , 2012, 256, 573-580.	2.1	152
83	Truncated DNMT3B Isoform DNMT3B7 Suppresses Growth, Induces Differentiation, and Alters DNA Methylation in Human Neuroblastoma. <i>Cancer Research</i> , 2012, 72, 4714-4723.	0.4	35
84	Using Germline Genomics to Individualize Pediatric Cancer Treatments. <i>Clinical Cancer Research</i> , 2012, 18, 2791-2800.	3.2	25
85	Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: A report from the INRG project. <i>European Journal of Cancer</i> , 2012, 48, 1185-1191.	1.3	14
86	Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. <i>Targeted Oncology</i> , 2012, 7, 199-210.	1.7	28
87	Opsoclonus-myoclonus and anti-Hu positive limbic encephalitis in a patient with neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2012, 58, 472-474.	0.8	17
88	Outcome After Surgery Alone or With Restricted Use of Chemotherapy for Patients With Low-Risk Neuroblastoma: Results of Children's Oncology Group Study P9641. <i>Journal of Clinical Oncology</i> , 2012, 30, 1842-1848.	0.8	174
89	Locoregional MYCN-amplified neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2012, 59, 736-738.	0.8	0
90	Sorafenib inhibits neuroblastoma cell proliferation and signaling, blocks angiogenesis, and impairs tumor growth. <i>Pediatric Blood and Cancer</i> , 2012, 59, 642-647.	0.8	23

#	ARTICLE	IF	CITATIONS
91	New aspects of neuroblastoma treatment: ASPHO 2011 symposium review. <i>Pediatric Blood and Cancer</i> , 2012, 58, 1099-1105.	0.8	26
92	Pilot Induction Regimen Incorporating Pharmacokinetically Guided Topotecan for Treatment of Newly Diagnosed High-Risk Neuroblastoma: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4351-4357.	0.8	124
93	Guidelines for Imaging and Staging of Neuroblastic Tumors: Consensus Report from the International Neuroblastoma Risk Group Project. <i>Radiology</i> , 2011, 261, 243-257.	3.6	386
94	Changes over three decades in outcome and the prognostic influence of age-at-diagnosis in young patients with neuroblastoma: A report from the International Neuroblastoma Risk Group Project. <i>European Journal of Cancer</i> , 2011, 47, 561-571.	1.3	94
95	Clinical and Biologic Features Predictive of Survival After Relapse of Neuroblastoma: A Report From the International Neuroblastoma Risk Group Project. <i>Journal of Clinical Oncology</i> , 2011, 29, 3286-3292.	0.8	248
96	The quinoxaline anti-tumor agent (R+)XK469 inhibits neuroblastoma tumor growth. <i>Pediatric Blood and Cancer</i> , 2011, 56, 164-167.	0.8	23
97	ABCC Multidrug Transporters in Childhood Neuroblastoma: Clinical and Biological Effects Independent of Cytotoxic Drug Efflux. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1236-1251.	3.0	113
98	Phase II Study of Oral Capsular 4-Hydroxyphenylretinamide (4-HPR/Fenretinide) in Pediatric Patients with Refractory or Recurrent Neuroblastoma: A Report from the Children's Oncology Group. <i>Clinical Cancer Research</i> , 2011, 17, 6858-6866.	3.2	88
99	Prognostic Value of the Stage 4S Metastatic Pattern and Tumor Biology in Patients With Metastatic Neuroblastoma Diagnosed Between Birth and 18 Months of Age. <i>Journal of Clinical Oncology</i> , 2011, 29, 4358-4364.	0.8	69
100	Phase II Study of Irinotecan and Temozolomide in Children With Relapsed or Refractory Neuroblastoma: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 208-213.	0.8	127
101	Racial and Ethnic Disparities in Risk and Survival in Children With Neuroblastoma: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 76-82.	0.8	109
102	Secreted Protein Acidic and Rich in Cysteine Is a Matrix Scavenger Chaperone. <i>PLoS ONE</i> , 2011, 6, e23880.	1.1	52
103	Advances in the treatment of neuroblastoma. <i>Clinical Advances in Hematology and Oncology</i> , 2011, 9, 865-7.	0.3	0
104	Pharmacokinetics of orally administered ABT-751 in children with neuroblastoma and other solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 66, 737-743.	1.1	16
105	Epigenetic alterations differ in phenotypically distinct human neuroblastoma cell lines. <i>BMC Cancer</i> , 2010, 10, 286.	1.1	22
106	Clinical outcome in children with recurrent neuroblastoma treated with ABT-751 and effect of ABT-751 on proliferation of neuroblastoma cell lines and on tubulin polymerization in vitro. <i>Pediatric Blood and Cancer</i> , 2010, 54, 47-54.	0.8	22
107	Phase II Randomized Comparison of Topotecan Plus Cyclophosphamide Versus Topotecan Alone in Children With Recurrent or Refractory Neuroblastoma: A Children's Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 3808-3815.	0.8	100
108	Antitumor Activity of Hu14.18-IL2 in Patients With Relapsed/Refractory Neuroblastoma: A Children's Oncology Group (COG) Phase II Study. <i>Journal of Clinical Oncology</i> , 2010, 28, 4969-4975.	0.8	220

#	ARTICLE	IF	CITATIONS
109	Anti-angiogenic SPARC peptides inhibit progression of neuroblastoma tumors. <i>Molecular Cancer</i> , 2010, 9, 138.	7.9	44
110	Outcome after Reduced Chemotherapy for Intermediate-Risk Neuroblastoma. <i>New England Journal of Medicine</i> , 2010, 363, 1313-1323.	13.9	253
111	Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma. <i>New England Journal of Medicine</i> , 2010, 363, 1324-1334.	13.9	1,460
112	Modulation of matrix remodeling by SPARC in neoplastic progression. <i>Seminars in Cell and Developmental Biology</i> , 2010, 21, 55-65.	2.3	128
113	Significance of <i>MYCN</i> Amplification in International Neuroblastoma Staging System Stage 1 and 2 Neuroblastoma: A Report From the International Neuroblastoma Risk Group Database. <i>Journal of Clinical Oncology</i> , 2009, 27, 365-370.	0.8	111
114	The International Neuroblastoma Risk Group (INRG) Staging System: An INRG Task Force Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 298-303.	0.8	869
115	Progress in Defining and Treating High-Risk Neuroblastoma: Lessons From the Bench and Bedside. <i>Journal of Clinical Oncology</i> , 2009, 27, 1003-1004.	0.8	17
116	Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: A report from the CCG and COG. <i>Pediatric Blood and Cancer</i> , 2009, 53, 563-569.	0.8	79
117	Presence of cancer-associated fibroblasts inversely correlates with Schwannian stroma in neuroblastoma tumors. <i>Modern Pathology</i> , 2009, 22, 950-958.	2.9	44
118	The International Neuroblastoma Risk Group (INRG) Classification System: An INRG Task Force Report. <i>Journal of Clinical Oncology</i> , 2009, 27, 289-297.	0.8	1,540
119	Are molecular neuroblastoma classifiers ready for prime time?. <i>Lancet Oncology</i> , The, 2009, 10, 641-642.	5.1	6
120	Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2008, 50, 679-680.	0.8	17
121	Lung metastases in neuroblastoma at initial diagnosis: A report from the International Neuroblastoma Risk Group (INRG) project. <i>Pediatric Blood and Cancer</i> , 2008, 51, 589-592.	0.8	58
122	Management of Tumor Lysis Syndrome: Need for Evidence-Based Guidelines. <i>Journal of Clinical Oncology</i> , 2008, 26, 5657-5658.	0.8	17
123	A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2008, 14, 1111-1115.	3.2	45
124	Clinical Significance of <i>MYCN</i> Amplification and Ploidy in Favorable-Stage Neuroblastoma: A Report From the Children's Oncology Group. <i>Journal of Clinical Oncology</i> , 2008, 26, 913-918.	0.8	67
125	3 + 3 (Rolling) 6. <i>Journal of Clinical Oncology</i> , 2008, 26, 170-171.	0.8	11
126	Methylation of CASP8, DCR2, and HIN-1 in Neuroblastoma Is Associated with Poor Outcome. <i>Clinical Cancer Research</i> , 2007, 13, 3191-3197.	3.2	98



#	ARTICLE	IF	CITATIONS
127	Prominent Microvascular Proliferation in Clinically Aggressive Neuroblastoma. <i>Clinical Cancer Research</i> , 2007, 13, 3499-3506.	3.2	35
128	Thrombospondin-1 Peptide ABT-510 Combined with Valproic Acid Is an Effective Antiangiogenesis Strategy in Neuroblastoma. <i>Cancer Research</i> , 2007, 67, 1716-1724.	0.4	84
129	Neuroblastoma. <i>Lancet, The</i> , 2007, 369, 2106-2120.	6.3	1,856
130	High-resolution analysis of 3p deletion in neuroblastoma and differential methylation of the SEMA3B tumor suppressor gene. <i>Cancer Genetics and Cytogenetics</i> , 2007, 174, 100-110.	1.0	34
131	Excellent local tumor control regardless of extent of surgical resection after treatment on the Chicago Pilot II protocol for neuroblastoma. <i>Journal of Pediatric Surgery</i> , 2006, 41, 271-276.	0.8	16
132	Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: Saving for a rainy day. <i>Pediatric Blood and Cancer</i> , 2006, 46, 719-722.	0.8	19
133	SPARC expression is associated with impaired tumor growth, inhibited angiogenesis and changes in the extracellular matrix. <i>International Journal of Cancer</i> , 2006, 118, 310-316.	2.3	100
134	The MYCN Enigma: Significance of MYCN Expression in Neuroblastoma. <i>Cancer Research</i> , 2006, 66, 2826-2833.	0.4	78
135	Association of High-Level MRP1 Expression With Poor Clinical Outcome in a Large Prospective Study of Primary Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1546-1553.	0.8	155
136	Does MYCN Amplification Manifested as Homogeneously Staining Regions at Diagnosis Predict a Worse Outcome in Children with Neuroblastoma? A Children's Oncology Group Study. <i>Clinical Cancer Research</i> , 2006, 12, 5693-5697.	3.2	35
137	A Phase 1 Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 7 Days Every 21 Days in Pediatric Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 4882-4887.	3.2	45
138	Positive association between congenital anomalies and risk of neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2005, 45, 649-655.	0.8	27
139	Treatment of Neuroblastoma. <i>Pediatric Oncology</i> , 2005, , 123-192.	0.5	2
140	Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 547-553.	1.9	127
141	Hyperdiploidy Plus Nonamplified MYCN Confers a Favorable Prognosis in Children 12 to 18 Months Old With Disseminated Neuroblastoma: A Pediatric Oncology Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 6466-6473.	0.8	135
142	Outcomes of Children With Intermediate-Risk Neuroblastoma After Treatment Stratified by MYCN Status and Tumor Cell Ploidy. <i>Journal of Clinical Oncology</i> , 2005, 23, 8819-8827.	0.8	74
143	Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. <i>New England Journal of Medicine</i> , 2005, 353, 2243-2253.	13.9	495
144	The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives. <i>Cancer Letters</i> , 2005, 228, 257-266.	3.2	48

#	ARTICLE	IF	CITATIONS
145	Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects. <i>Cancer Letters</i> , 2005, 228, 283-299.	3.2	53
146	“Cross-talk” between Schwannian stroma and neuroblasts promotes neuroblastoma tumor differentiation and inhibits angiogenesis. <i>Cancer Letters</i> , 2005, 228, 125-131.	3.2	26
147	Cross-Talk between Schwann Cells and Neuroblasts Influences the Biology of Neuroblastoma Xenografts. <i>American Journal of Pathology</i> , 2005, 166, 891-900.	1.9	43
148	Protocol for the Examination of Specimens From Patients With Neuroblastoma and Related Neuroblastic Tumors. <i>Archives of Pathology and Laboratory Medicine</i> , 2005, 129, 874-883.	1.2	22
149	Association of Epigenetic Inactivation of RASSF1A with Poor Outcome in Human Neuroblastoma. <i>Clinical Cancer Research</i> , 2004, 10, 8493-8500.	3.2	81
150	Scintigraphic Response by 123I-Metaiodobenzylguanidine Scan Correlates With Event-Free Survival in High-Risk Neuroblastoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 3909-3915.	0.8	89
151	Methylation-Associated Silencing of the Heat Shock Protein 47 Gene in Human Neuroblastoma. <i>Cancer Research</i> , 2004, 64, 4531-4538.	0.4	35
152	Neuroblastoma Angiogenesis Is Inhibited with a Folded Synthetic Molecule Corresponding to the Epidermal Growth Factor-Like Module of the Follistatin Domain of SPARC. <i>Cancer Research</i> , 2004, 64, 7420-7425.	0.4	47
153	Treatment of Relapsed Wilms’ Tumor With High-Dose Therapy and Autologous Hematopoietic Stem-Cell Rescue: The Experience at Children’s Memorial Hospital. <i>Journal of Clinical Oncology</i> , 2004, 22, 2885-2890.	0.8	64
154	MYCN-mediated regulation of the MRP1 promoter in human neuroblastoma. <i>Oncogene</i> , 2004, 23, 753-762.	2.6	76
155	MYCN amplification remains prognostically strong 20 years after its “clinical debut”. <i>European Journal of Cancer</i> , 2004, 40, 2639-2642.	1.3	58
156	The regulation of angiogenesis in neuroblastoma. <i>Cancer Letters</i> , 2003, 197, 47-52.	3.2	36
157	Advances in the Diagnosis and Treatment of Neuroblastoma. <i>Oncologist</i> , 2003, 8, 278-292.	1.9	233
158	Methylation-associated silencing of the thrombospondin-1 gene in human neuroblastoma. <i>Cancer Research</i> , 2003, 63, 6299-310.	0.4	85
159	Treatment of High-Risk Neuroblastoma With Triple-Tandem High-Dose Therapy and Stem-Cell Rescue: Results of the Chicago Pilot II Study. <i>Journal of Clinical Oncology</i> , 2002, 20, 2284-2292.	0.8	128
160	HuD, a Neuronal-specific RNA-binding Protein, Increases their Vivo Stability of MYCN RNA. <i>Journal of Biological Chemistry</i> , 2002, 277, 1967-1973.	1.6	53
161	SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. <i>Cancer Research</i> , 2002, 62, 7357-63.	0.4	134
162	Detection of MYCN Gene Amplification in Neuroblastoma by Fluorescence In Situ Hybridization: A Pediatric Oncology Group Study. <i>Neoplasia</i> , 2001, 3, 105-109.	2.3	79

#	ARTICLE	IF	CITATIONS
163	Treatment and Outcome of 83 Children With Intraspinal Neuroblastoma: The Pediatric Oncology Group Experience. <i>Journal of Clinical Oncology</i> , 2001, 19, 1047-1055.	0.8	100
164	Residential Pesticide Exposure and Neuroblastoma. <i>Epidemiology</i> , 2001, 12, 20-27.	1.2	77
165	Natural killer cell lymphoma. <i>Cancer</i> , 2001, 91, 642-646.	2.0	32
166	Antiangiogenic therapy inhibits human neuroblastoma growth. <i>Medical and Pediatric Oncology</i> , 2001, 36, 190-193.	1.0	16
167	Expression of the putative tumour suppressor gene, p73, in neuroblastoma and other childhood tumours. <i>Medical and Pediatric Oncology</i> , 2001, 36, 48-51.	1.0	3
168	Gastrointestinal relapse of leukemia, mimicking acute graft vs. host disease, following a stem cell transplant. , 2000, 34, 287-289.		7
169	Schwann cell-conditioned medium inhibits angiogenesis in vitro and in vivo. <i>Medical and Pediatric Oncology</i> , 2000, 35, 590-592.	1.0	6
170	Prognostic significance of EPHB6, EFNB2, and EFNB3 expressions in neuroblastoma. <i>Medical and Pediatric Oncology</i> , 2000, 35, 656-658.	1.0	25
171	MYCN Expression Is Not Prognostic of Adverse Outcome in Advanced-Stage Neuroblastoma With Nonamplified MYCN. <i>Journal of Clinical Oncology</i> , 2000, 18, 3604-3613.	0.8	100
172	Synergy between 5' and 3' flanking regions of the human tyrosine hydroxylase gene ensures specific, high-level expression in neuroblastoma cells. <i>Neuroscience Letters</i> , 2000, 292, 147-150.	1.0	7
173	Natural History and Biology of Stage A Neuroblastoma: A Pediatric Oncology Group Study. <i>The American Journal of Pediatric Hematology/Oncology</i> , 2000, 22, 197-205.	1.3	87
174	Long-term outcome of patients with intraspinal neuroblastoma. , 1999, 32, 353-359.		66
175	Clinical Impact and Prognostic Value of Metaiodobenzylguanidine Imaging in Children With Metastatic Neuroblastoma. <i>Journal of Pediatric Hematology/Oncology</i> , 1999, 21, 13-18.	0.3	54
176	Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chemotherapy in pediatric patients. <i>Biology of Blood and Marrow Transplantation</i> , 1998, 4, 38-42.	2.0	15
177	Advances in the diagnosis and treatment of neuroblastoma. <i>Current Opinion in Oncology</i> , 1998, 10, 43-51.	1.1	28
178	Modulation of N-myc expression alters the invasiveness of neuroblastoma. <i>Clinical and Experimental Metastasis</i> , 1997, 15, 130-139.	1.7	36
179	Long-term neurologic outcome in children with opsoclonus-myoclonus associated with neuroblastoma: A report from the Pediatric Oncology Group. , 1997, 28, 284-288.		151
180	Neuroblastoma: solving a biologic puzzle. <i>Cancer Treatment and Research</i> , 1997, 92, 125-162.	0.2	1

#	ARTICLE	IF	CITATIONS
181	Expression of the Gene for Multidrug-Resistance-Associated Protein and Outcome in Patients with Neuroblastoma. <i>New England Journal of Medicine</i> , 1996, 334, 231-238.	13.9	295
182	Differential Activity of ELAV-like RNA-binding Proteins in Human Neuroblastoma. <i>Journal of Biological Chemistry</i> , 1996, 271, 33587-33591.	1.6	34
183	Binding of a 40-kDa Protein to the N-myc 3' Untranslated Region Correlates with Enhanced N-myc Expression in Human Neuroblastoma. <i>Journal of Biological Chemistry</i> , 1996, 271, 33580-33586.	1.6	34
184	Co-amplification and concomitant high levels of expression of a DEAD box gene with MYCN in human neuroblastoma. <i>Genes Chromosomes and Cancer</i> , 1995, 14, 196-203.	1.5	56
185	A Pilot Study of Isotretinoin in the Treatment of Juvenile Chronic Myelogenous Leukemia. <i>New England Journal of Medicine</i> , 1994, 331, 1680-1684.	13.9	99
186	Long-term outcome in children with opsoclonus-myoclonus and ataxia and coincident neuroblastoma. <i>Journal of Pediatrics</i> , 1994, 125, 712-716.	0.9	117
187	Preferential amplification of the paternal allele of the N-myc gene in human neuroblastomas. <i>Nature Genetics</i> , 1993, 4, 191-194.	9.4	65
188	Evidence for Molecular Heterogeneity in Human Ganglioneuroblastoma. <i>Pediatric Pathology</i> , 1993, 13, 787-796.	0.5	18
189	Smallest region of overlap in Wilms tumor deletions uniquely implicates an 11p13 zinc finger gene as the disease locus. <i>Genomics</i> , 1991, 10, 293-297.	1.3	54
190	Single copies of the N-myc oncogene in neuroblastomas from children presenting with the syndrome of opsoclonus-myoclonus. <i>Cancer</i> , 1988, 62, 723-726.	2.0	47
191	The spectrum of metabolic bone disease in lymphoblastic leukemia. <i>Cancer</i> , 1987, 59, 346-350.	2.0	43
192	Present Status of Serum Tumor Markers in Diagnosis, Prognosis, and Evaluation of Therapy. <i>Cancer Investigation</i> , 1986, 4, 305-327.	0.6	22